v3.26.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Angi Inc.
IAC
Redeemable Noncontrolling Interests
Total IAC Shareholders' Equity
Total IAC Shareholders' Equity
Angi Inc.
Total IAC Shareholders' Equity
IAC
Common Stock
Common Stock, $0.0001 par value
Common Stock
Class B Common Stock, $0.0001 par value
Additional Paid-in Capital
Additional Paid-in Capital
Angi Inc.
(Accumulated Deficit) Retained Earnings
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Angi Inc.
Treasury Stock
Treasury Stock
IAC
Noncontrolling Interests
Noncontrolling Interests
Angi Inc.
Balance at beginning of period at Dec. 31, 2022       $ 27,235                            
Increase (Decrease) in Temporary Equity [Roll Forward]                                    
Net earnings (loss)       (1,175)                            
Adjustment of noncontrolling interests to redemption amount       7,567                            
Other       (249)                            
Balance at end of period at Dec. 31, 2023       33,378                            
Balance at beginning of period at Dec. 31, 2022 $ 6,572,534       $ 5,931,614     $ 8 $ 1 $ 6,295,080   $ (265,019) $ (13,133)   $ (85,323)   $ 640,920  
Balance at beginning of period (in shares) at Dec. 31, 2022               84,184 5,789                  
Increase (Decrease) in Shareholders' Equity                                    
Net earnings (loss) 259,492       265,942             265,942         (6,450)  
Other comprehensive income (loss), net of income taxes 2,699       2,186               2,186       513  
Stock-based compensation expense 121,950       73,562         73,562             48,388  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (9,814) $ (6,288)     (9,814) $ (5,615)       (9,814) $ (5,620)     $ 5       $ (673)
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               281                    
Purchase of treasury stock (165,600) (11,099) $ (167,118)     (11,099) $ (167,118)       (11,099)         $ (167,118)    
Adjustment of noncontrolling interests to redemption amount (7,567)       (7,567)         (7,567)                
Adjustment to the liquidation value of Vivian Health preferred shares 0       5,527         5,527             (5,527)  
Other 214       243         243             (29)  
Balance at end of period at Dec. 31, 2023 6,755,003       6,077,861     $ 8 $ 1 6,340,312   923 (10,942)   (252,441)   677,142  
Balance at end of period (in shares) at Dec. 31, 2023               84,465 5,789                  
Increase (Decrease) in Temporary Equity [Roll Forward]                                    
Net earnings (loss)       587                            
Adjustment of noncontrolling interests to redemption amount       (6,970)                            
Other       (1,580)                            
Balance at end of period at Dec. 31, 2024 25,415     25,415                            
Increase (Decrease) in Shareholders' Equity                                    
Net earnings (loss) (533,917)       (539,897)             (539,897)         5,980  
Other comprehensive income (loss), net of income taxes (877)       (465)               (465)       (412)  
Stock-based compensation expense 118,364       77,745         77,745             40,619  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (14,845) (7,353)     (14,845) 4,024       (14,845) 4,013     $ 11       (11,377)
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               366                    
Purchase of treasury stock   (28,581)       (28,581)         (28,581)              
Purchase of noncontrolling interests (16,019)       (11,296)         (11,296)             (4,723)  
Adjustment of noncontrolling interests to redemption amount 6,970       6,970         6,970                
Adjustment to the liquidation value of Vivian Health preferred shares 0       6,154         6,154             (6,154)  
Other 228       228         228                
Balance at end of period at Dec. 31, 2024 6,278,973       5,577,898     $ 8 $ 1 6,380,700   (538,974) (11,396)   (252,441)   701,075  
Balance at end of period (in shares) at Dec. 31, 2024               84,831 5,789                  
Increase (Decrease) in Temporary Equity [Roll Forward]                                    
Net earnings (loss)       381                            
Adjustment of noncontrolling interests to redemption amount       (498)                            
Other       (34)                            
Balance at end of period at Dec. 31, 2025 25,264     $ 25,264                            
Increase (Decrease) in Shareholders' Equity                                    
Net earnings (loss) (101,851)       (104,026)             (104,026)         2,175  
Other comprehensive income (loss), net of income taxes 365       (68)               (68)       433  
Stock-based compensation expense 31,661       29,163         29,163             2,498  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (70,683) (4,572)     (70,683) (8,260)       (70,683) (8,264)   4         $ 3,688
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               1,750                    
Forfeiture of the Company’s former CEO’s restricted common stock award (in shares)               (3,000)                    
Withholding taxes paid on the Company’s transfer of Angi Inc. Class B shares to its former CEO (9,347)       (9,347)         (9,347)                
Purchase of treasury stock (316,100) $ (10,688) $ (318,591)     $ (10,688) $ (318,591)       $ (10,688)         $ (318,591)    
Adjustment of noncontrolling interests to redemption amount 498       498         498                
Adjustment to the liquidation value of Vivian Health preferred shares 0       (2,990)         (2,990)             2,990  
Distribution of the Company’s investment in Angi Inc. (1,032,380)       (1,032,380)         (1,031,998)     (382)          
Elimination of Angi Inc. noncontrolling interest 0       682,927         682,927             (682,927)  
Other 374       374         374                
Balance at end of period at Dec. 31, 2025 $ 4,763,759       $ 4,733,827     $ 8 $ 1 $ 5,959,692   $ (643,000) $ (11,842)   $ (571,032)   $ 29,932  
Balance at end of period (in shares) at Dec. 31, 2025               83,581 5,789